National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials (PDQ®)
Patient Version   Health Professional Version
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Maintenance Rituximab for Follicular Lymphoma

Azacitidine Improves Survival in MDS

Second Stem Cell Transplant Not Helpful in Myeloma
Related Links
Educational Materials About Clinical Trials

Clinical Trials: Questions and Answers

Questions to Ask Your Doctor

Drug Information from MedlinePlus
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase III, Phase IITreatmentActive18 and overPharmaceutical / IndustryCRAD001C2241
NCT00419159

Trial Description

Summary

To assess the efficacy and safety of everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with other chemotherapy

Eligibility Criteria

Inclusion criteria

  • Age ≥ 18 years old.
  • Patients with metastatic colorectal cancer (CRC).
  • Patients must have tumor tissue from original surgical resection.
  • Patients with documented disease progression within 6 months of their most recent dose of chemotherapeutic regimens
  • Patients with at least one measurable lesion

Exclusion criteria

  • Patients currently receiving anti-cancer agents or who have received these within 4 weeks prior to study entry.
  • Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients.
  • Chronic treatment with steroids or another immunosuppressive agent.
  • Patients with untreated central nervous system (CNS) metastases or neurologically unstable CNS metastases.
  • HIV seropositivity.
  • Patients with an active, bleeding diathesis. Patients may use enoxaparin.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
  • Patients who are using other investigational agents or who had received investigational drugs ≤ 4 weeks prior to first study treatment.

Other protocol defined inclusion/exclusion criteria may apply

Trial Contact Information

Trial Lead Organizations/Sponsors

Novartis Pharmaceuticals Corporation

NovartisStudy Chair

Novartis U.S.Ph: 862 778 8300

Novartis BaselPh: 41 61 324 1111

Trial Sites

U.S.A.
Nevada
  Las Vegas
 Study Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00419159
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov